Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System
Official title: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System in a 'Real-World' Patient Population
Run by Sahajanand Medical Technologies Limited · NCT03443999 · Data updated 2026-11-12
This study is testing a new type of heart stent to see if it is safe and effective for people with coronary artery disease who need stents.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Sahajanand Medical Technologies Limited Industry-sponsored |
| Locations | 7 sites (Breda, North Brabant and 6 other locations) |
| Status | Recruiting |
| Started | February 27, 2018 |
| Main results expected | June 2027 |
| Study ends | December 2027 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT03443999 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who require elective implantation of the Supraflex Family stent.
✕Probably not a fit
Patients who are pregnant, lactating, or have a high probability of non-adherence to follow-up requirements may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to assess the safety and efficacy of the Supraflex Family sirolimus-eluting coronary stent system in patients requiring stent implantation for coronary artery disease. It focuses on a new generation of drug-eluting stents that utilize a biodegradable polymer and a cobalt-chromium platform, which enhances flexibility and deliverability while maintaining strength. The study will collect data from a real-world patient population to evaluate the stent's performance in routine clinical practice.
Why it matters
Potential benefit: If successful, this study could provide insights into the long-term safety and effectiveness of a new stent technology for patients with coronary artery disease.
How similar studies have gone: Other studies have shown promise with biodegradable polymer stents, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. The patient, or legal representative, has been informed of the nature of the registry and has consented to participate and authorised the collection and release of his/her medical information by signing a Patient Informed Consent Form 3. Treating physician has electively implanted at least one Supraflex Family stent as part of the patient's planned clinical care. 4. The patient is willing and able to cooperate with study procedures and required follow up visits Exclusion Criteria: 1. Women with known pregnancy or who are lactating 2. High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) 3. Currently participating in another study that has not completed the primary endpoint or that clinically interferes with the current registry requirements 4. Planned surgery within 6-month of PCI unless dual anti-platelet therapy is maintained throughout the peri-surgical period
Where it's running
-
Amphia Ziekenhuis
Breda, North Brabant, Netherlands Recruiting -
Catharina Ziekenhuis
Eindhoven, North Brabant, Netherlands Recruiting -
Tergooi Ziekenhuis
Blaricum, North Holland, Netherlands Recruiting -
Medical Center Leeuwarden
Leeuwarden, Provincie Friesland, Netherlands Recruiting -
Albert Schweitzer Ziekenhuis
Dordrecht, South Holland, Netherlands Recruiting -
Maasstad Ziekenhuis
Rotterdam, South Holland, Netherlands Recruiting
Show 1 more location
-
ZorgSaam Hospital
Terneuzen, Zeeuws- Vlaanderen, Netherlands Recruiting
Study contacts
- Principal investigator: Dr. A.J.J. IJsselmuiden, MD. — Amphia Hospital, Breda, The Netherlands
- Study coordinator: Vibhor Bhatia
- Email: vibhor.bhatia@sahmed.com
- Phone: +919049528863
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.